Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016’, provides in depth analysis on Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
  
• The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics and enlists all their major and minor projects
  
• The report assesses Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report summarizes all the dormant and discontinued pipeline projects
  
• The report reviews latest news and deals related to Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
  
• Identify the use of drugs for target identification and drug repurposing
  
• Identify potential new clients or partners in the target demographic
  
• Develop strategic initiatives by understanding the focus areas of leading companies
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) development landscape
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Overview 6
Therapeutics Development 7
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Stage of Development 7
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Therapy Area 8
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Indication 9
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Companies 12
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Universities/Institutes 14
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Companies Involved in Therapeutics Development 22
Cerecor Inc. 22
CureVac GmbH 23
Eisai Co., Ltd. 24
Inovio Pharmaceuticals, Inc. 25
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Drug Profiles 26
CV-9103 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
E-2072 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
INO-5150 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule for Neuropathic Pain - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Dormant Projects 33
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Discontinued Products 35
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Featured News & Press Releases 36
Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer 36
Jul 07, 2015: CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer 36
Nov 19, 2012: Experimental Drug Improves Memory In Mice With Multiple Sclerosis, Researchers Report 37
Jun 10, 2011: CureVac Presents Promising New Data For Prostate Cancer Vaccine CV9103 At ASCO Conference 39
Feb 02, 2011: Inovio''s Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial 40
Oct 04, 2010: CureVac Presents Data From Phase I/IIa Clinical Study With CV9103 In Hormone-Refractory Prostate Cancer 40
Nov 02, 2009: CureVac Launches Phase IIa mRNA Vaccine Trial In Prostate Cancer 41
May 01, 2009: CureVac Receives FDA Approval to Start its Phase I / IIa Trial in the U.S. with an mRNA Vaccine for the Treatment of Prostate Cancer 41
Jan 05, 2009: CureVac Receives IND Approval From FDA To Start Its Phase I/IIa mRNA Vaccine Clinical Trial In Prostate Cancer 42
Oct 12, 2008: CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Cerecor Inc., H1 2016 22
Pipeline by CureVac GmbH, H1 2016 23
Pipeline by Eisai Co., Ltd., H1 2016 24
Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 25
Dormant Projects, H1 2016 33
Dormant Projects (Contd..1), H1 2016 34
Discontinued Products, H1 2016 35

List of Figures

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Routes of Administration, H1 2016 18
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Molecule Types, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 20